Additional file 1 of Risk thresholds for patients to switch between daily tablets and biweekly infusions in second-line treatment for advanced hepatocellular carcinoma: a patient preference study
Creators: name: Parikh, Neehar D.
name: Girvan, Allicia
name: Coulter, Joshua
name: Gable, Jonathon
name: Poon, Jiat Ling
name: Kim, Sangmi
name: Chatterjee, Anindya
name: Boeri, Marco
Publisher: name: figshare
Year: 2023
Subjects: subject: Medicine
subject: Biotechnology
subject: Cancer
subject: 110309 Infectious Diseases
subject: FOS: Health sciences

description: Additional file 1: Table S1. Summary of Respondents’ Experience with Hepatocellular Carcinoma Treatments. Table S2. Results of Covariate-Adjusted Threshold Model: Tablet Sample (N = 92). Table S3. Results of Covariate-Adjusted Threshold Model: Intravenous Infusion Sample (N = 58). Figure S1. Threshold Question Sequence for Risk of Decreased Appetite if “Four Tablets” is Initially Preferred. Figure S2. Threshold Question Sequence for Risk of Hand-Foot Skin Reaction if “Four Tablets” is Initially Preferred. Figure S3. Threshold Question Sequence for Risk of Diarrhea if “Four Tablets” is Initially Preferred. Figure S4. Threshold Question Sequence for Risk of Ascites if “Four Tablets” is Initially Preferred. Figure S5. Threshold Question Sequence for Risk of Proteinuria if “Four Tablets” is Initially Preferred. Figure S6. Threshold Question Sequence for Risk of Peripheral Edema if “Four Tablets” is Initially Preferred. Figure S7. Threshold Question Sequence for Risk of Hypertension if Intravenous Infusion is Initially Preferred. Figure S8. Threshold Question Sequence for Risk of Decreased Appetite if Intravenous Infusion is Initially Preferred. Figure S9. Threshold Question Sequence for Risk of Hand-Foot Skin Reaction if Intravenous Infusion is Initially Preferred. Figure S10. Threshold Question Sequence for Risk of Diarrhea if Intravenous Infusion is Initially Preferred. Figure S11. Threshold Question Sequence for Risk of Ascites if Intravenous Infusion is Initially Preferred. Figure S12. Threshold Question Sequence for Risk of Proteinuria if Intravenous Infusion is Initially Preferred. Figure S13. Threshold Question Sequence for Risk of Peripheral Edema if Intravenous Infusion is Initially Preferred. Figure S14. Minimum Reduction in Risk of Hypertension to Switch From Tablets Every Day to Intravenous Infusion Every 2 Weeks. Figure S15. Minimum Reduction in Risk of Decreased Appetite to Switch From Tablets Every Day to Intravenous Infusion Every 2 Weeks. Figure S16. Minimum Reduction in Risk of Hand-Foot Skin Reaction to Switch From Tablets Every Day to Intravenous Infusion Every 2 Weeks. Figure S17. Minimum Reduction in Risk of Diarrhea to Switch From Tablets Every Day To Intravenous Infusion Every 2 Weeks. Figure S18. Minimum Reduction in Risk of Ascites to Switch From Tablets Every Day to Intravenous Infusion Every 2 Weeks. Figure S19. Minimum Reduction in Risk of Proteinuria to Switch From Tablets Every Day to Intravenous Infusion Every 2 Weeks. Figure S20. Minimum Reduction in Risk of Peripheral Edema to Switch From Tablets Every Day to Intravenous Infusion Every 2 Weeks. Figure S21. Maximum Increase in Risk of Hypertension to Keep Intravenous Infusion Every 2 Weeks Instead of Switching to Tablets Every Day. Figure S22. Maximum Increase in Risk of Lower Appetite to Keep Intravenous Infusion Every 2 Weeks Instead of Switching to Tablets Every Day. Figure S23. Maximum Increase in Risk of Hand-foot Reaction to Keep Intravenous Infusion Every 2 Weeks Instead of Switching to Tablets Every Day. Figure S24. Maximum Increase in Risk of Diarrhea to Keep Intravenous Infusion Every 2 Weeks Instead of Switching to Tablets Every Day. Figure S25. Maximum Increase in Risk of Ascites to Keep Intravenous Infusion Every 2 Weeks Instead of Switching to Tablets Every Day. Figure S26. Maximum Increase in Risk of Proteinuria to Keep Intravenous Infusion Every 2 Weeks Instead of Switching to Tablets Every Day. Figure S27. Maximum Increase in Risk of Peripheral Edema to Keep Intravenous Infusion Every 2 Weeks Instead of Switching to Tablets Every Day.